Takashi Sakakibara

Takashi Sakakibara

Auto-generated profile, based on publicly available information

Takashi Sakakibara

Department of Pharmacy, Kariya Toyota General Hospital, Kariya-city, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAkiko Shiotani
Akiko Shiotani
TMTakahisa Murao
Takahisa Murao
YFYoshihiko Fujita
Yoshihiko Fujita
YFYoshinori Fujimura
Yoshinori Fujimura
TSTakashi Sakakibara
Takashi Sakakibara
KHKen Haruma
Ken Haruma
Aspirin-induced enteropathy is now increasingly being recognized although the pathogenesis of small intestinal damage induced by aspirin is not well understood and related risk factors have not been established. To investigate pharmacogenomic profile of low dose aspirin (LDA)-induced small bowel bleeding. Genome-wide analysis of single nucleotide polymorphisms (SNPs) was performed using the Affymetrix DMET™ Plus Premier Pack. Genotypes of candidate genes associated with small bowel bleeding were determined using TaqMan SNP Genotyping Assay kits and direct sequencing. In the validation study in overall 37 patients with small bowel bleeding and 400 controls, 4 of 27 identified SNPs: CYP4F11 (rs1060463) GG (p=0.003), CYP2D6 (rs28360521) GG (p=0.02), CYP24A1 (rs4809957) T allele (p=0.04), and GSTP1 (rs1695) G allele (p=0.04) were significantly more frequent in the small bowel bleeding group compared to the controls. After adjustment for significant factors, CYP2D6 (rs28360521) GG (OR 4.11, 95% CI. 1.62 -10.4) was associated with small bowel bleeding. CYP4F11 and CYP2D6 SNPs may identify patients at increased risk for aspirin-induced small bowel bleeding.

1 January 2015 in Journal of Toxicologic Pathology
Verified
Journal Article
Open access
PDF file
MFMasatoshi Furukawa
Masatoshi Furukawa
TSTakashi Sakakibara
Takashi Sakakibara
KIKouta Itoh
Kouta Itoh
KKKohtaro Kawamura
Kohtaro Kawamura
SSSatoshi Sasaki
Satoshi Sasaki
MMMasao Matsuura
Masao Matsuura
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

30 November 2021 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
MHMasakazu Hatano
Masakazu Hatano
ITIppei Takeuchi
Ippei Takeuchi
KYKanade Yamashita
Kanade Yamashita
AMAoi Morita
Aoi Morita
KTKaori Tozawa
Kaori Tozawa
HKHiroyuki Kamei
Hiroyuki Kamei
Masakazu Hatano, Ippei Takeuchi, Kanade Yamashita, Aoi Morita, Kaori Tozawa, Takashi Sakakibara, Genta Hajitsu, Manako Hanya, Shigeki Yamada, Nakao Iwata, Hiroyuki Kamei. Clin Psychopharmacol Neurosci 2021;19:610-7. https://doi.org/10.9758/cpn.2021.19.4.610

14 December 2021 in Renal Replacement Therapy
Verified
Journal Article
Open access
PDF file
TKTeruhisa Kinoshita
Teruhisa Kinoshita
SOSayuri Otsuka
Sayuri Otsuka
STShota Torii
Shota Torii
YTYoko Tsugeno
Yoko Tsugeno
SFShiori Fukaya
Shiori Fukaya
NTNorio Takimoto
Norio Takimoto
Background: Although not indicated in the USA, edoxaban tosylate hydrate 15 mg is used for venous thromboembolism (VTE) prophylaxis after orthopedic surgery of the lower extremities in Japan. However, its efficacy and safety in patients with impaired renal function have not been fully evaluated. We aimed to investigate the intervention’s effectiveness in these patients. Methods: From 2018 to 2020, patients who underwent total hip arthroplasty, total knee arthroplasty, hip fracture surgery, or knee arthroplasty single granule replacement and with renal dysfunction were evaluated. Safety was evaluated according to bleeding occurrence during edoxaban treatment and liver function endpoints. Patients were divided into the 15- and 30-mg oral groups, including 23 patients with impaired renal function and 209 with normal renal function, respectively. Results: VTE incidence in the 15- and 30-mg groups was 8.7% and 8.6%, respectively; the intergroup difference was insignificant (odds ratio [OR] 0.99; 95% confidence interval [CI] 0.22–4.56; p = 1.00). Bleeding did not occur in the 15-mg group and was noted in 9 patients in the 30-mg group during treatment with edoxaban; the intergroup difference was insignificant (p = 1.00). The increase in aspartate aminotransferase and alanine aminotransferase levels was 30% in the 15-mg group and 19% in the 30-mg group, with no difference between the groups (p = 0.27). Multivariate analysis showed that the dose of edoxaban was not a significant factor associated with the incidence of VTE (adjusted OR 2.31; 95% CI 0.39–13.8; p = 0.36). Conclusions: Edoxaban 15 mg in patients with impaired renal function may be as effective as edoxaban 30 mg in patients with normal renal function. However, the number of cases included in this study was small and the power was insufficient; therefore, a study with a larger sample size is desirable.